Who are montelukast and cetirizine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/montelukast-and-cetirizine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

montelukast and cetirizine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

montelukast and cetirizine (montelukast and cetirizine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene receptor antagonist and H1-receptor antagonist combination. Area: Immunology / Allergy.

marketed Leukotriene receptor antagonist and H1-receptor antagonist combination CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

montelukast and cetirizine (montelukast and cetirizine) — Medical University of Lodz. This combination blocks leukotriene receptors (montelukast) and histamine H1 receptors (cetirizine) to reduce allergic inflammation and symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
montelukast and cetirizine TARGET	montelukast and cetirizine	Medical University of Lodz	marketed	Leukotriene receptor antagonist and H1-receptor antagonist combination	CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene receptor antagonist and H1-receptor antagonist combination class)

Medical University of Lodz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). montelukast and cetirizine — Competitive Intelligence Brief. https://druglandscape.com/ci/montelukast-and-cetirizine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab